This inventor holds 1 USPTO granted patent and 3 published patent applications. Top assignees: Harbin Hongdoushan Bio-Pharm Co., Ltd., Heilongjiang Hongdoushan Pharmaceutical Co., Ltd., Shanghai Kairun Biology Medicine Limited Liability Company. Active years: 2017.
Company Filing History:
1 out of 1 
1 out of 1 
1 out of 1 Years Active: 2017
Title: Xuehai Wu: Innovator in Thromboembolic Disease Treatment
Introduction
Xuehai Wu is a notable inventor based in Shanghai, China. He has made significant contributions to the field of medicine, particularly in the development of treatments for thromboembolic diseases. His innovative approach has led to the creation of a unique drug formulation that utilizes depolymerized holothurian glycosaminoglycans (DHG).
Latest Patents
Xuehai Wu holds a patent for the "Application of depolymerized holothurian glycosaminoglycans (DHG) in preparation of drug for prevention and treatment of thromboembolic diseases." This invention discloses the application of DHG, which has weight-average molecular weights between 26,000 and 45,000 Da. The drug demonstrates a significant anticoagulant effect when administered intravenously or subcutaneously, while also exhibiting minimal side effects. The formulation is effective for the prevention and treatment of thromboembolic diseases, enhancing blood coagulation time and improving safety and convenience for users.
Career Highlights
Throughout his career, Xuehai Wu has worked with various companies, including Shanghai Kairun Biology Medicine Limited Liability Company and Harbin Hongdoushan Biopharm Co., Ltd. His work in these organizations has contributed to advancements in biomedicine and drug development.
Collaborations
Xuehai Wu has collaborated with notable colleagues such as Zhiguo Wang and Quanhai Liu. These partnerships have fostered innovation and research in the field of thromboembolic disease treatment.
Conclusion
Xuehai Wu's contributions to medical science, particularly through his patent on DHG, highlight his role as an innovator in the treatment of thromboembolic diseases. His work continues to impact the field positively, paving the way for safer and more effective medical treatments.